ATE304011T1 - Hydantoin-enthaltende glucokinase aktivatoren - Google Patents

Hydantoin-enthaltende glucokinase aktivatoren

Info

Publication number
ATE304011T1
ATE304011T1 AT01925563T AT01925563T ATE304011T1 AT E304011 T1 ATE304011 T1 AT E304011T1 AT 01925563 T AT01925563 T AT 01925563T AT 01925563 T AT01925563 T AT 01925563T AT E304011 T1 ATE304011 T1 AT E304011T1
Authority
AT
Austria
Prior art keywords
glucocinase
activators
hydantoin containing
hydantoin
glucocinase activators
Prior art date
Application number
AT01925563T
Other languages
English (en)
Inventor
Robert Alan Goodnow Jr
Kang Le
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE304011T1 publication Critical patent/ATE304011T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT01925563T 2000-05-03 2001-04-23 Hydantoin-enthaltende glucokinase aktivatoren ATE304011T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20149800P 2000-05-03 2000-05-03
PCT/EP2001/004555 WO2001083478A2 (en) 2000-05-03 2001-04-23 Hydantoin-containing glucokinase activators

Publications (1)

Publication Number Publication Date
ATE304011T1 true ATE304011T1 (de) 2005-09-15

Family

ID=22746054

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01925563T ATE304011T1 (de) 2000-05-03 2001-04-23 Hydantoin-enthaltende glucokinase aktivatoren

Country Status (20)

Country Link
US (2) US6583288B2 (de)
EP (1) EP1280801B1 (de)
JP (1) JP3842131B2 (de)
KR (1) KR100505312B1 (de)
CN (1) CN1209361C (de)
AR (1) AR034253A1 (de)
AT (1) ATE304011T1 (de)
AU (2) AU5227001A (de)
BR (1) BR0110492A (de)
CA (1) CA2407428C (de)
DE (1) DE60113247T2 (de)
DK (1) DK1280801T3 (de)
EC (1) ECSP014055A (de)
ES (1) ES2248309T3 (de)
MX (1) MXPA02010746A (de)
PE (1) PE20011313A1 (de)
PT (1) PT1280801E (de)
UY (1) UY26689A1 (de)
WO (1) WO2001083478A2 (de)
ZA (1) ZA200208370B (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1209361C (zh) * 2000-05-03 2005-07-06 霍夫曼-拉罗奇有限公司 含乙内酰脲的葡糖激酶激活剂
US6482951B2 (en) * 2000-12-13 2002-11-19 Hoffmann-La Roche Inc. Isoindolin-1-one glucokinase activators
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
RU2374236C2 (ru) 2001-12-21 2009-11-27 Ново Нордиск А/С Амидные производные в качестве активаторов gk
AU2003243921B2 (en) 2002-06-27 2009-05-07 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
KR101124245B1 (ko) 2002-06-27 2012-07-02 노보 노르디스크 에이/에스 치료제로서 아릴 카르보닐 유도체
JP2006509774A (ja) 2002-10-03 2006-03-23 ノバルティス アクチエンゲゼルシャフト ２型糖尿病の処置において有用なグルコキナーゼアクチベーターとしての置換（チアゾール−２−イル）−アミドまたはスルホンアミド
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
US7132425B2 (en) * 2002-12-12 2006-11-07 Hoffmann-La Roche Inc. 5-substituted-six-membered heteroaromatic glucokinase activators
JP4621198B2 (ja) * 2003-02-11 2011-01-26 プロシディオン・リミテッド トリ（シクロ）置換アミドグルコキナーゼ活性化化合物
PL378117A1 (pl) 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
WO2005066145A1 (en) 2004-01-06 2005-07-21 Novo Nordisk A/S Heteroaryl-ureas and their use as glucokinase activators
CN1910166B (zh) * 2004-01-06 2012-01-04 诺和诺德公司 杂芳基脲及其作为葡糖激酶活化剂的用途
EP1737870A1 (de) 2004-04-02 2007-01-03 Novartis AG Thiazolopyridinderivate, pharmazeutische zusammensetzungen, die diese enthalten, und verfahren zur behandlung von durch glucokinase vermittelten leiden
CN1960995B (zh) 2004-04-02 2010-12-08 诺瓦提斯公司 作为葡糖激酶活化剂、可用于治疗ⅱ型糖尿病的磺酰胺-噻唑并吡啶衍生物
KR20090006885A (ko) * 2004-08-17 2009-01-15 에프. 호프만-라 로슈 아게 치환 히단토인
WO2006031491A2 (en) * 2004-09-09 2006-03-23 Merck & Co., Inc. Tricyclic anilide spirolactam cgrp receptor antagonists
US7390798B2 (en) * 2004-09-13 2008-06-24 Merck & Co., Inc. Carboxamide spirolactam CGRP receptor antagonists
ATE464305T1 (de) 2004-09-13 2010-04-15 Merck Sharp & Dohme Bicyclische anilidspirolactame als antagonisten des cgrp-rezeptors
TW200621766A (en) * 2004-09-17 2006-07-01 Hoffmann La Roche Substituted hydantoins
CA2614518A1 (en) 2005-07-08 2007-01-18 Novo-Nordisk A/S Dicycloalkyl urea glucokinase activators
US7642259B2 (en) 2005-07-09 2010-01-05 Astrazeneca Ab Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
WO2007015805A1 (en) 2005-07-20 2007-02-08 Eli Lilly And Company 1-amino linked compounds
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
JP2009509988A (ja) 2005-09-29 2009-03-12 サノフィ−アベンティス フェニル−及びピリジニル−１，２，４−オキサジアゾロン誘導体、その製造方法、及び医薬品としてのその使用
GT200600428A (es) 2005-09-30 2007-05-21 Compuestos organicos
GT200600429A (es) 2005-09-30 2007-04-30 Compuestos organicos
WO2007123581A1 (en) 2005-11-17 2007-11-01 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
WO2007061923A2 (en) * 2005-11-18 2007-05-31 Takeda San Diego, Inc. Glucokinase activators
FR2894962B1 (fr) * 2005-12-20 2008-03-14 Pharmamens Sarl Hydantoines a action insulinotropique
US7612212B2 (en) * 2006-02-22 2009-11-03 Hoffmann-La Roche Inc. Substituted hydantoins
US8034822B2 (en) 2006-03-08 2011-10-11 Takeda San Diego, Inc. Glucokinase activators
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
US8008332B2 (en) 2006-05-31 2011-08-30 Takeda San Diego, Inc. Substituted indazoles as glucokinase activators
US20080107725A1 (en) * 2006-10-13 2008-05-08 Albano Antonio A Pharmaceutical Solid Dosage Forms Comprising Amorphous Compounds Micro-Embedded in Ionic Water-Insoluble Polymers
WO2008079787A2 (en) 2006-12-20 2008-07-03 Takeda San Diego, Inc. Glucokinase activators
TW200831081A (en) 2006-12-25 2008-08-01 Kyorin Seiyaku Kk Glucokinase activator
CN101687800B (zh) * 2007-03-07 2012-03-21 杏林制药株式会社 葡糖激酶活化物质
CA2680307A1 (en) * 2007-03-12 2008-09-18 Merck & Co., Inc. Monocyclic anilide spirolactam cgrp receptor antagonists
US8173645B2 (en) 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
US7557221B2 (en) 2007-08-16 2009-07-07 Hoffman-La Roche Inc. Substituted hydantoins
MX2010006331A (es) * 2007-12-20 2010-07-05 Hoffmann La Roche Hidantoinas sustituidas como inhibidores de cinasa mek.
US8258134B2 (en) * 2008-04-16 2012-09-04 Hoffmann-La Roche Inc. Pyridazinone glucokinase activators
MY163114A (en) 2008-04-28 2017-08-15 Kyorin Seiyaku Kk Cyclopentylacrylamide derivative
TWI445707B (zh) 2008-05-16 2014-07-21 Takeda California Inc 葡萄糖激酶活化劑
US8450494B2 (en) 2009-06-22 2013-05-28 Cadila Healthcare Limited Disubstituted benzamide derivatives as glucokinase (GK) activators
EA201270217A1 (ru) 2009-07-31 2012-09-28 Кадила Хелзкэр Лимитед Замещенные бензамидные производные в качестве активаторов глюкокиназы (гк)
JP5909482B2 (ja) 2010-03-31 2016-04-26 ザ スクリプス リサーチ インスティテュート 細胞の再プログラム
ES2671881B1 (es) * 2016-11-11 2019-03-25 Consejo Superior Investigacion Procedimiento de obtencion de polimeros con grupos isocianato
KR20210020866A (ko) 2018-06-12 2021-02-24 브이티브이 테라퓨틱스 엘엘씨 인슐린 또는 인슐린 유사체와 조합된 글루코키나제 활성제의 치료적 용도
WO2021167840A1 (en) 2020-02-18 2021-08-26 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof
EP4161640A4 (de) 2020-06-08 2024-01-17 vTv Therapeutics LLC Salze oder cokristalle von {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido)-thiazol-5-ylsulfanyl}-essigsäure und verwendungen davon

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202339A (en) * 1987-08-28 1993-04-13 Mochida Pharmaceutical Co., Ltd. Hydantoin derivatives
US6320050B1 (en) * 1999-03-29 2001-11-20 Hoffmann-La Roche Inc. Heteroaromatic glucokinase activators
CN1209361C (zh) * 2000-05-03 2005-07-06 霍夫曼-拉罗奇有限公司 含乙内酰脲的葡糖激酶激活剂

Also Published As

Publication number Publication date
ECSP014055A (es) 2002-01-25
PE20011313A1 (es) 2001-12-28
KR100505312B1 (ko) 2005-08-04
CN1209361C (zh) 2005-07-06
US20030225286A1 (en) 2003-12-04
DE60113247D1 (de) 2005-10-13
EP1280801A2 (de) 2003-02-05
BR0110492A (pt) 2003-04-08
US6583288B2 (en) 2003-06-24
CA2407428A1 (en) 2001-11-08
JP3842131B2 (ja) 2006-11-08
AU2001252270B2 (en) 2005-12-15
CN1427838A (zh) 2003-07-02
CA2407428C (en) 2010-02-02
JP2003531905A (ja) 2003-10-28
US20010056191A1 (en) 2001-12-27
EP1280801B1 (de) 2005-09-07
UY26689A1 (es) 2001-11-30
WO2001083478A3 (en) 2002-05-16
MXPA02010746A (es) 2003-03-10
KR20020093120A (ko) 2002-12-12
WO2001083478A2 (en) 2001-11-08
DE60113247T2 (de) 2006-06-22
US6784298B2 (en) 2004-08-31
AR034253A1 (es) 2004-02-18
PT1280801E (pt) 2005-11-30
DK1280801T3 (da) 2006-01-23
AU5227001A (en) 2001-11-12
ES2248309T3 (es) 2006-03-16
ZA200208370B (en) 2004-01-26

Similar Documents

Publication Publication Date Title
ATE304011T1 (de) Hydantoin-enthaltende glucokinase aktivatoren
DK1169312T3 (da) Glucokinaseaktivatorer
DK1242397T3 (da) Trans-olefiniske glucokinaseaktivatorer
ATE297921T1 (de) Tetrazolylphenyl-acetamide als glukokinaseaktivatoren
DE60134470D1 (de) Para-amin substituierte phenylamid glukokinase activatoren
NO20030472L (no) Imidazolderivater
AR028253A1 (es) Inhibidores de la glucogeno fosforilasa
DE60131992D1 (de) Pfropfcopolymere enthaltende klebstoffe
DK1529530T5 (da) Glucokinase påvirkende forbindelser
DE60042550D1 (de) Mutierte varianten des insulin-ähnlichen wachstumsfaktor i (igf-i)
ATE360620T1 (de) Imidazolderivate
ATE388040T1 (de) Träger
DE50009640D1 (de) Drehmaschine
DE50011953D1 (de) Bohrwerkzeug
NO20025659L (no) Heterocykliske forbindelser
DE50100739D1 (de) Drehmaschine
DE50011611D1 (de) Bohrwerkzeug
DE50113112D1 (de) Schaltungsanordnung
DE50102328D1 (de) Feuchttücher (i)
FI20001260L (fi) Kontti
DE50104260D1 (de) Behälter
DE50115426D1 (de) Schaltungsanordnung
FI20000173L (fi) Nesteen syöttäminen
FI20001704A0 (fi) Kontti
DK1282612T3 (da) Heteroaromatiske alkylphenyl-glucokinaseaktivatorer

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1280801

Country of ref document: EP

REN Ceased due to non-payment of the annual fee